Invivyd announces PEMGARDA neutralizes dominant SARS-CoV-2 variant XEC in vitro

Invivyd, Inc.

New data show PEMGARDA (pemivibart) maintains neutralizing activity against XEC, which with KP.3.1.1 accounts for 69% of U.S. variants per CDC.
Data submitted to FDA; update to PEMGARDA Fact Sheet for Healthcare Providers expected.
Pemivibart has shown consistent activity across 39 distinct SARS-CoV-2 variants over nearly three years.
Company does not anticipate meaningful change to neutralization if epitope remains intact as since Omicron BA.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.